Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial
- PMID: 28007348
- PMCID: PMC5358809
- DOI: 10.1016/S0140-6736(16)32567-3
Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial
Erratum in
-
Department of Error.Lancet. 2017 Jan 28;389(10067):368. doi: 10.1016/S0140-6736(16)32594-6. Epub 2016 Dec 21. Lancet. 2017. PMID: 28010992 No abstract available.
-
Department of Error.Lancet. 2017 Feb 4;389(10068):e2. doi: 10.1016/S0140-6736(17)30228-3. Lancet. 2017. PMID: 28170337 No abstract available.
Abstract
Background: The safety and effectiveness of a continuous, day-and-night automated glycaemic control system using insulin and glucagon has not been shown in a free-living, home-use setting. We aimed to assess whether bihormonal bionic pancreas initialised only with body mass can safely reduce mean glycaemia and hypoglycaemia in adults with type 1 diabetes who were living at home and participating in their normal daily routines without restrictions on diet or physical activity.
Methods: We did a random-order crossover study in volunteers at least 18 years old who had type 1 diabetes and lived within a 30 min drive of four sites in the USA. Participants were randomly assigned (1:1) in blocks of two using sequentially numbered sealed envelopes to glycaemic regulation with a bihormonal bionic pancreas or usual care (conventional or sensor-augmented insulin pump therapy) first, followed by the opposite intervention. Both study periods were 11 days in length, during which time participants continued all normal activities, including athletics and driving. The bionic pancreas was initialised with only the participant's body mass. Autonomously adaptive dosing algorithms used data from a continuous glucose monitor to control subcutaneous delivery of insulin and glucagon. The coprimary outcomes were the mean glucose concentration and time with continuous glucose monitoring (CGM) glucose concentration less than 3·3 mmol/L, analysed over days 2-11 in participants who completed both periods of the study. This trial is registered with ClinicalTrials.gov, number NCT02092220.
Findings: We randomly assigned 43 participants between May 6, 2014, and July 3, 2015, 39 of whom completed the study: 20 who were assigned to bionic pancreas first and 19 who were assigned to the comparator first. The mean CGM glucose concentration was 7·8 mmol/L (SD 0·6) in the bionic pancreas period versus 9·0 mmol/L (1·6) in the comparator period (difference 1·1 mmol/L, 95% CI 0·7-1·6; p<0·0001), and the mean time with CGM glucose concentration less than 3·3 mmol/L was 0·6% (0·6) in the bionic pancreas period versus 1·9% (1·7) in the comparator period (difference 1·3%, 95% CI 0·8-1·8; p<0·0001). The mean nausea score on the Visual Analogue Scale (score 0-10) was greater during the bionic pancreas period (0·52 [SD 0·83]) than in the comparator period (0·05 [0·17]; difference 0·47, 95% CI 0·21-0·73; p=0·0024). Body mass and laboratory parameters did not differ between periods. There were no serious or unexpected adverse events in the bionic pancreas period of the study.
Interpretation: Relative to conventional and sensor-augmented insulin pump therapy, the bihormonal bionic pancreas, initialised only with participant weight, was able to achieve superior glycaemic regulation without the need for carbohydrate counting. Larger and longer studies are needed to establish the long-term benefits and risks of automated glycaemic management with a bihormonal bionic pancreas.
Funding: National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, and National Center for Advancing Translational Sciences.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5358809/bin/nihms848403f1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5358809/bin/nihms848403f2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5358809/bin/nihms848403f3.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5358809/bin/nihms848403f4.gif)
Comment in
-
Automated insulin delivery: what's new, needed, and next?Lancet. 2017 Jan 28;389(10067):333-334. doi: 10.1016/S0140-6736(16)32591-0. Epub 2016 Dec 20. Lancet. 2017. PMID: 28007347 No abstract available.
Similar articles
-
Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials.Lancet Diabetes Endocrinol. 2017 Jul;5(7):501-512. doi: 10.1016/S2213-8587(17)30167-5. Epub 2017 May 19. Lancet Diabetes Endocrinol. 2017. PMID: 28533136 Review.
-
Glucagon in artificial pancreas systems: Potential benefits and safety profile of future chronic use.Diabetes Obes Metab. 2017 Jan;19(1):13-23. doi: 10.1111/dom.12789. Epub 2016 Nov 9. Diabetes Obes Metab. 2017. PMID: 27629286 Review.
-
Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial.Lancet Diabetes Endocrinol. 2016 Mar;4(3):233-243. doi: 10.1016/S2213-8587(15)00489-1. Epub 2016 Feb 3. Lancet Diabetes Endocrinol. 2016. PMID: 26850709 Free PMC article. Clinical Trial.
-
Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.Lancet Diabetes Endocrinol. 2015 Jan;3(1):17-26. doi: 10.1016/S2213-8587(14)70226-8. Epub 2014 Nov 27. Lancet Diabetes Endocrinol. 2015. PMID: 25434967 Clinical Trial.
-
Outpatient glycemic control with a bionic pancreas in type 1 diabetes.N Engl J Med. 2014 Jul 24;371(4):313-325. doi: 10.1056/NEJMoa1314474. Epub 2014 Jun 15. N Engl J Med. 2014. PMID: 24931572 Free PMC article. Clinical Trial.
Cited by
-
14. Children and Adolescents: Standards of Care in Diabetes-2024.Diabetes Care. 2024 Jan 1;47(Suppl 1):S258-S281. doi: 10.2337/dc24-S014. Diabetes Care. 2024. PMID: 38078582 Review.
-
Randomized Trial of the Insulin-Only iLet Bionic Pancreas for the Treatment of Cystic Fibrosis- Related Diabetes.Diabetes Care. 2024 Jan 1;47(1):101-108. doi: 10.2337/dc23-1411. Diabetes Care. 2024. PMID: 37874987 Clinical Trial.
-
The Evolution of Insulin Administration in Type 1 Diabetes.J Diabetes Mellitus. 2021 Nov;11(5):249-277. doi: 10.4236/jdm.2021.115021. Epub 2021 Nov 17. J Diabetes Mellitus. 2021. PMID: 37745178 Free PMC article.
-
The artificial pancreas: two alternative approaches to achieve a fully closed-loop system with optimal glucose control.J Endocrinol Invest. 2024 Mar;47(3):513-521. doi: 10.1007/s40618-023-02193-2. Epub 2023 Sep 15. J Endocrinol Invest. 2024. PMID: 37715091 Free PMC article. Review.
-
Intelligent Insulin vs. Artificial Intelligence for Type 1 Diabetes: Will the Real Winner Please Stand Up?Int J Mol Sci. 2023 Aug 24;24(17):13139. doi: 10.3390/ijms241713139. Int J Mol Sci. 2023. PMID: 37685946 Free PMC article. Review.
References
-
- The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986. - PubMed
-
- Tamborlane RW, Bergenstal RM, Miller KM, DuBose SN, Hall CA. T1D Exchange Clinic Network. The T1D Exchange Clinic Registry. J Clin Endocrinol Metab. 2012;97:4383–4389. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical